CACNG2

Across TCGA pan-cancer cohorts, CACNG2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CACNG2 data layer compared with 18 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher CACNG2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CACNG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PAAD, LAML, and CHOL are the cancer types where CACNG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.006	0.505	<.001	15	view →
LAML	DFS	Median	All	0.056	0.572	.001	12	view →
CHOL	OS	Median	All	0.154	0.793	.004	9	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.921	0.306	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CACNG2–PAAD (DFS)

Open the PAAD breakdown →